We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Specific Phenotype Narrows Risk of Preeclampsia

By LabMedica International staff writers
Posted on 10 Sep 2019
Print article
Image: Preeclampsia is a condition that occurs only during pregnancy and some symptoms may include high blood pressure and protein in the urine. A specific phenotype narrows the risk of preeclampsia (Photo courtesy of the American Pregnancy Association).
Image: Preeclampsia is a condition that occurs only during pregnancy and some symptoms may include high blood pressure and protein in the urine. A specific phenotype narrows the risk of preeclampsia (Photo courtesy of the American Pregnancy Association).
Preeclampsia can lead to a baby being born early and can put the mother at risk of a seizure or stroke during delivery. It can also lead to damage in the kidneys, liver, lungs, heart or eyes and can increase a patient's risk for cardiovascular disease in the future.

The general female population has a 5% chance of developing preeclampsia during pregnancy, but that chance increases to 20% for diabetic women. Haptoglobin (Hp), a protein with functional genetic polymorphisms, has antioxidant, anti-inflammatory and angiogenic effects. Among people with diabetes, Hp 2-2 phenotype is associated with cardio-renal disease.

Endocrinologists at the Medical University of South Carolina (Charleston, SC, USA) and their colleagues investigated whether Hp phenotype is associated with preeclampsia (PE) in type 1 diabetes (T1DM), and/or modulates lipoprotein-associated risks. Included in the multicenter prospective study were 47pregnant women with T1DM (normal albuminuria, normotensive at enrolment, studied at three visits (V1-V3), all preceding PE onset: 12.3±1.9, 21.8±1.5, and 31.5±1.6 weeks gestation (mean ± SD). The main outcome measures were Hp phenotype and lipoprotein profiles in 23 women with versus 24 without subsequent PE.

The scientists reported that Hp phenotype did not predict PE, but lipoprotein associations with subsequent PE were confined to Hp 2-2 women, in whom the following associations with PE were observed: increased LDL-cholesterol, LDL particle concentration, Apolipoprotein B (APOB), triacylglycerol/high density lipoprotein cholesterol ratio, and APOB:APOA1 ratio; decreased HDL-cholesterol, APOA1, large HDL particle concentration, and peripheral lipoprotein lipolysis. In women with one or two Hp-1 alleles, no such associations were observed.

Clare B. Kelly, PhD, an Endocrinologist and first author of the study, said, “By studying these patients, we have identified different markers that could help predict the complication before its onset. Currently, we're taking the more reactive approach when it comes to preeclampsia. But if we know a patient is diabetic and has the 2-2 phenotype, we can monitor her more closely throughout her pregnancy and treat it proactively.” The study was originally published online on June 20, 2019, in The Journal of Clinical Endocrinology & Metabolism.

Related Links:
Medical University of South Carolina

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.